Everhart Financial Group Inc. Invests $787,000 in LifeStance Health Group, Inc. $LFST

Everhart Financial Group Inc. purchased a new stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 111,751 shares of the company’s stock, valued at approximately $787,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. AustralianSuper Pty Ltd bought a new stake in shares of LifeStance Health Group in the 3rd quarter valued at about $17,056,000. Vanguard Group Inc. raised its holdings in LifeStance Health Group by 19.5% in the third quarter. Vanguard Group Inc. now owns 14,613,535 shares of the company’s stock worth $80,374,000 after purchasing an additional 2,383,728 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in LifeStance Health Group by 62.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock worth $26,363,000 after purchasing an additional 1,839,465 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of LifeStance Health Group by 27.2% during the third quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after buying an additional 1,790,694 shares during the last quarter. Finally, Integral Health Asset Management LLC purchased a new stake in shares of LifeStance Health Group during the third quarter valued at about $8,250,000. 85.50% of the stock is currently owned by institutional investors.

Insider Transactions at LifeStance Health Group

In other LifeStance Health Group news, Director Darren M. Black sold 4,314,939 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $7.01, for a total value of $30,247,722.39. Following the completion of the transaction, the director owned 29,209,776 shares of the company’s stock, valued at approximately $204,760,529.76. This trade represents a 12.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 3.20% of the company’s stock.

LifeStance Health Group Price Performance

Shares of LFST stock opened at $6.40 on Friday. LifeStance Health Group, Inc. has a fifty-two week low of $3.74 and a fifty-two week high of $8.09. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of 320.16 and a beta of 1.11. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.65 and a current ratio of 1.65. The stock’s 50-day simple moving average is $7.00 and its 200-day simple moving average is $6.35.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.02). The company had revenue of $382.20 million during the quarter, compared to analysts’ expectations of $378.51 million. LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.65%. The business’s revenue for the quarter was up 17.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.01) earnings per share. As a group, equities analysts forecast that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current fiscal year.

LifeStance Health Group declared that its Board of Directors has initiated a share buyback program on Wednesday, February 25th that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the company to reacquire up to 3.6% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Wall Street Zen raised shares of LifeStance Health Group from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. Canaccord Genuity Group increased their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. BTIG Research raised their target price on shares of LifeStance Health Group from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Jefferies Financial Group raised shares of LifeStance Health Group to a “strong-buy” rating in a report on Thursday, March 12th. Finally, UBS Group upped their price target on LifeStance Health Group from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.83.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.